4591 RIBOMIC Inc.リボミックTSE Growth / Pharmaceuticals
0 posts
RIBOMIC Inc. stock plunged on Nov 20: what happened
It closed at ¥50.0 on Nov 20 (−¥8.0, −13.79%), ranking #16 among the top losers of all stocks on the Tokyo Stock Exchange.
Disclosures around that day
- 11/19 18:002027年3月期第2四半期(中間期)決算説明会資料
Changes are calculated from the closing prices this site collects daily; limit-up/down is an estimate based on the daily price limit. Please make your own investment decisions.
RIBOMIC Inc. (4591) at a glance
Prices are from Yahoo! Finance and may be delayed. Always check the latest price before trading.
RIBOMIC Inc. (4591) Stock Price HistoryNear an all-time low
RIBOMIC Inc. closed at ¥50.0 on Nov 20, 2026, −21.9% over 1 month, −38.3% over 1 year.
If you had invested ¥100,000 1 month ago, it would be worth ¥78,125 today (−21.9%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −11.9%, while this stock moved −21.9%.
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 20 (Fri) | ¥50.0 | −8 | −13.79% |
| Nov 19 (Thu) | ¥58.0 | +2 | +3.57% |
| Nov 17 (Tue) | ¥56.0 | +0 | +0.00% |
| Nov 16 (Mon) | ¥56.0 | −2 | −3.45% |
| Nov 13 (Fri) | ¥58.0 | +1 | +1.75% |
| Nov 12 (Thu) | ¥57.0 | −1 | −1.72% |
| Nov 11 (Wed) | ¥58.0 | −2 | −3.33% |
| Nov 10 (Tue) | ¥60.0 | +4 | +7.14% |
| Nov 6 (Fri) | ¥56.0 | −4 | −6.67% |
| Nov 5 (Thu) | ¥60.0 | −3 | −4.76% |
If you had invested ¥100,000 3 months ago, it would be worth ¥60,241 today (−39.8%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −14.8%, while this stock moved −39.8%.
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 20 (Fri) | ¥50.0 | −8 | −13.79% |
| Nov 19 (Thu) | ¥58.0 | +2 | +3.57% |
| Nov 17 (Tue) | ¥56.0 | +0 | +0.00% |
| Nov 16 (Mon) | ¥56.0 | −2 | −3.45% |
| Nov 13 (Fri) | ¥58.0 | +1 | +1.75% |
| Nov 12 (Thu) | ¥57.0 | −1 | −1.72% |
| Nov 11 (Wed) | ¥58.0 | −2 | −3.33% |
| Nov 10 (Tue) | ¥60.0 | +4 | +7.14% |
| Nov 6 (Fri) | ¥56.0 | −4 | −6.67% |
| Nov 5 (Thu) | ¥60.0 | −3 | −4.76% |
If you had invested ¥100,000 6 months ago, it would be worth ¥69,444 today (−30.6%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −5.6%, while this stock moved −30.6%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥50.0 | −21.9% |
| Oct 2026 | ¥64.0 | −20.0% |
| Sep 2026 | ¥80.0 | −15.8% |
| Aug 2026 | ¥95.0 | +30.1% |
| Jul 2026 | ¥73.0 | +19.7% |
| Jun 2026 | ¥61.0 | −12.9% |
| May 2026 | ¥70.0 | −11.4% |
If you had invested ¥100,000 1 year ago, it would be worth ¥61,728 today (−38.3%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +13.3%, while this stock moved −38.3%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥50.0 | −21.9% |
| Oct 2026 | ¥64.0 | −20.0% |
| Sep 2026 | ¥80.0 | −15.8% |
| Aug 2026 | ¥95.0 | +30.1% |
| Jul 2026 | ¥73.0 | +19.7% |
| Jun 2026 | ¥61.0 | −12.9% |
| May 2026 | ¥70.0 | −11.4% |
| Apr 2026 | ¥79.0 | −10.2% |
| Mar 2026 | ¥88.0 | +2.3% |
| Feb 2026 | ¥86.0 | +2.4% |
| Jan 2026 | ¥84.0 | +7.7% |
| Dec 2025 | ¥78.0 | −8.2% |
| Nov 2025 | ¥85.0 | ― |
If you had invested ¥100,000 3 years ago, it would be worth ¥41,322 today (−58.7%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +67.8%, while this stock moved −58.7%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥50.0 | −35.9% |
| 2025 | ¥78.0 | ― |
If you had invested ¥100,000 5 years ago, it would be worth ¥8,606 today (−91.4%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +96.3%, while this stock moved −91.4%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥50.0 | −35.9% |
| 2025 | ¥78.0 | ― |
If you had invested ¥100,000 in Oct 2014, it would be worth ¥3,631 today (−96.4%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +223.4%, while this stock moved −96.4%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥50.0 | −35.9% |
| 2025 | ¥78.0 | −6.0% |
| 2024 | ¥83.0 | −23.1% |
| 2023 | ¥108 | −41.0% |
| 2022 | ¥183 | −55.5% |
| 2021 | ¥411 | +13.5% |
| 2020 | ¥362 | −26.3% |
| 2019 | ¥491 | +22.4% |
| 2018 | ¥401 | −31.8% |
| 2017 | ¥588 | −16.5% |
| 2016 | ¥704 | −41.9% |
| 2015 | ¥1,212 | −8.9% |
| 2014 | ¥1,330 | ― |
Daily, weekly and monthly closes (Yahoo! Finance, split-adjusted, dividends excluded). "All" covers the range Yahoo provides (from Oct 2014). Please check the latest prices before trading.
RIBOMIC Inc. (4591) financial indicators
PER, ROE and dividend yield are based on company forecasts, calculated from earnings reports and the closing price after each trading day.
Key features of RIBOMIC Inc. (4591)
Business overview
The company is a biotech venture focused on researching and developing drugs based on aptamers, a type of nucleic acid medicine expected to be the next generation of drugs after antibodies. It creates aptamer drugs using its own drug discovery platform, the RiboART System, and aims to earn revenue by licensing them out to pharmaceutical companies. Its priority areas are eye diseases and rare diseases. Its most advanced candidate is umedaptanib pegol, an anti-FGF2 aptamer it created in-house, being developed to treat achondroplasia and wet age-related macular degeneration.
Summarized from the annual securities report (fiscal year ended March 2026) filed on EDINET.
Position within Pharmaceuticals (79 companies)
| PBR | 1.14x | Below the sector median of 1.86x (No. 21 from the lowest) |
|---|---|---|
| ROE | -58.59% | No. 47 in the sector (highest first); median 4.17% |
| Market cap | ¥2.8 bn | No. 73 in the sector (largest first) |
Ranks among stocks in the same Tokyo Stock Exchange sector (33 sectors). PER and PBR of zero or below (losses, negative equity) are excluded and ranked from the lowest.
Price milestones
| 52-week high | ¥108 | 3/11 |
|---|---|---|
| 52-week low | ¥50 | 11/20 |
| Current position | 0.0% | Where the low is 0% and the high is 100% (close on 11/20: ¥50) |
| Year to date | -35.9% | No. 59 of 77 in the sector (best first) |
| 1 year | -38.3% |
Based on closing prices (adjusted for stock splits, excluding dividends).
Kabutaro's ranking history
| Top 50 losers | 2 times | Latest: 11/20 (No. 16) |
|---|
Gainers and losers have been recorded since 9/2026.
Calculated as of 2026/11/20 17:30 JST. Updated every business day in the evening.
Recent disclosures (TDnet, in Japanese)
- 11/19 18:002027年3月期第2四半期(中間期)決算説明会資料
- 11/17 15:30軟骨無形成症治療薬(umedaptanib pegol)の国内第III相臨床試験:目標登録数達成のお知らせ
- 11/12 15:30営業外損失(為替差損)の計上に関するお知らせ
- 11/12 15:302027年3月期第2四半期(中間期)決算短信〔日本基準〕(非連結)
- 11/02 15:30第三者割当により発行された第19回新株予約権(行使価額修正条項付)の月間行使状況に関するお知らせ
- 10/22 15:30軟骨無形成症治療薬(umedaptanib pegol)の国内第III相臨床試験:目標登録数を上回る治験参加同意取得のお知らせ
- 10/20 15:30業績予想の修正に関するお知らせ
- 10/20 15:30DDSアプタマー技術に関する技術評価契約締結のお知らせ
- 10/06 15:30軟骨無形成症治療薬(umedaptanib pegol)第II相長期投与試験の経過報告と奏効患者における効果の継続性に関するお知らせ
- 10/01 15:30第三者割当により発行された第19回新株予約権(行使価額修正条項付)の月間行使状況に関するお知らせ
Show 1 more
Filings from the past 12 months (11).
Posts
This board is shared with the Japanese and Chinese versions. Feel free to write in English, Chinese or Japanese.
No posts yet. Be the first to write something.
Write on the RIBOMIC Inc. board
More Japanese stocks in English
- SanBio Company Limited4592
- HEALIOS K.K.4593
- BrightPath Biotherapeutics Co.,Ltd.4594
- MIZUHO MEDY CO.,LTD.4595
- Kubota Pharmaceutical Holdings Co.,Ltd.4596
- Solasia Pharma K.K.4597
- Delta-Fly Pharma,Inc.4598
- StemRIM Inc.4599
- Nomura High-yield J-REIT Index ETF459A
- BRANU Inc.460A
- Dai Nippon Toryo Company,Limited4611
- NIPPON PAINT HOLDINGS CO.,LTD.4612